Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
05/25 ASTELLAS PHARMA : Announces Record Number of Abstracts Highlighting Breadth and ..
05/19 ASTELLAS PHARMA : MSD submits application for approval of type-2 diabetes drug c..
05/18 ASTELLAS PHARMA : Data on Pain Reported by Researchers at Astellas Pharma (Effec..
05/18 ASTELLAS PHARMA : Announces Decision to Discontinue ASP8273 Treatment and Close ..
05/18 NANOSTRING TECHNOLOGIES, INC. (NASDA : NSTG) Files An 8-K Other Events
05/15 ASTELLAS PHARMA : Announces Continuation of Performance-linked Stock Compensatio..
05/12 ASTELLAS PHARMA : Announces Decision to Discontinue ASP8273 Treatment and Close ..
05/11 ASTELLAS PHARMA : The Institute of Medical Science, the University of Tokyo, and..
05/01 TRANSFER OF 16 LONG-LISTED PRODUCTS : Closing of Asset Purchase Agreement
04/28 TRANSFER OF 16 LONG-LISTED PRODUCTS : Closing of Asset Purchase Agreement
More news
Sector news : Pharmaceuticals - NEC
01:02p WARREN BUFFETT : Warren Buffett takes 3 percent stake in Germany's Lanxess
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 19, 2017
05/18 NanoString revises guidance after Astellas and Pfizer ax late-stage study of ..
05/15 Cytokinetics' CK-2127107 an Orphan Drug for spinal muscular atrophy
05/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : May 12, 2017
05/11 Astellas bails on late-stage lung cancer candidate ASP8273
Advertisement
Financials ( JPY)
Sales 2018 1 311 194 M
EBIT 2018 260 000 M
Net income 2018 203 782 M
Finance 2018 535 403 M
Yield 2018 2,53%
P/E ratio 2018 14,24
P/E ratio 2019 14,25
EV / Sales 2018 1,91x
EV / Sales 2019 1,81x
Capitalization 3 035 814 M
More Financials
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 1 623  JPY
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-13.31%27 253
JOHNSON & JOHNSON10.16%341 901
ROCHE HOLDING LTD.14.62%236 581
NOVARTIS AG6.07%211 457
PFIZER INC.-1.05%191 398
MERCK & CO., INC.10.28%177 567
More Results